COVID Vaccine Hopeful Lands $100M In Funding Round

Law360 (April 7, 2021, 3:00 PM EDT) -- Coronavirus vaccine developer Icosavax, working with Latham & Watkins LLP, said Wednesday that it's been injected with $100 million in a funding round led by health care and life sciences investor RA Capital Management.

Icosavax Inc. said in a news release that it plans to use the Series B financing to fund the development of respiratory virus vaccines and the evaluation of its own coronavirus vaccine.

Boston-based RA Capital Management LP was joined in the round by Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant Asset Management, Omega Funds, Citadel's Surveyor Capital and existing investors Qiming Venture Partners USA, Adams...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!